Results 141 to 150 of about 2,004 (157)

Ravulizumab in neuer Konzentration zugelassen

InFo Hämatologie + Onkologie, 2021
openaire   +1 more source

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies

European Journal of Haematology, 2022
Joo-Seop Chung, Jun Ho Jang
exaly  

Ravulizumab for COVID-19 Kidney Injury

Journal of the American Society of Nephrology, 2022
Aliza Anwar Memon, Hasban Ahmed, Andrew M. Siedlecki   +2 more
openaire   +1 more source

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Journal of Medical Economics, 2020
, Evan Popoff, Ioannis Tomazos
exaly  

Eculizumab/Ravulizumab

Reactions Weekly
openaire   +1 more source

Meningococcal vaccine conjugate/ravulizumab

Reactions Weekly, 2019
openaire   +1 more source

Ravulizumab auch gegen NMOSD wirksam

InFo Neurologie + Psychiatrie, 2023
openaire   +1 more source

Keine komplementvermittelten Durchbruchhämolysen mit Ravulizumab

Transfusionsmedizin, 2021
openaire   +1 more source

Plasma/Ravulizumab

Reactions Weekly
openaire   +1 more source

PNH: Neue Daten zu Ravulizumab

InFo Hämatologie + Onkologie, 2023
openaire   +1 more source